News | April 20, 2012

Cervical Scan to Reduce Post-Pap Biopsies Unveiled at British Medical Conference

April 20, 2012 — Guided Therapeutics Inc. announced this week that the LuViva Advanced Cervical Scan is being introduced to medical leaders at the 40th Anniversary Meeting of the British Society for Colposcopy and Cervical Pathology (BSCCP) in Gateshead, United Kingdom, by Eurosurgical Ltd., the company’s U.K. distributor. The meeting runs April 18-20.

In the U.K., LuViva is initially intended as a follow-up test after a positive Pap test. Today in the U.K., approximately 400,000 women annually are referred to more than 170 institutions for a follow-up or colposcopy examination, which often involves a biopsy of the cervix. Based on its clinical trial results, LuViva could eliminate approximately 40 percent of unnecessary follow-up procedures and could identify serious cervical disease up to two years earlier than the standard of care.

“The BSCCP meeting is an important gathering of leading women’s healthcare providers from across the U.K. and Ireland and an excellent venue to introduce LuViva ahead of its anticipated launch later this year,” said Mark L. Faupel, Ph.D., CEO and president of Guided Therapeutics Inc.

Eurosurgical purchased, and recently received, the first LuViva demonstration unit shipped to the European Union. Demonstration units are designed to educate the sales force and show the functionality of the product to medical professionals. The company anticipates CE mark approval in the second quarter of 2012.

“Eurosurgical is pleased to be at the forefront of improving women’s healthcare through new and innovative technologies like LuViva,” said Peter Parker, managing director of Eurosurgical Ltd.

LuViva is a diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of pre-cancerous cells that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow-up with a colposcopy examination, which in many cases involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva Cervical Guide single-use patient interface and calibration disposable.

The Guided Therapeutics LuViva Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use.

For more information:,

Related Content

Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Gary D. Luker Named Editor of Radiology: Imaging Cancer

Image courtesy of University of Michigan Medical School

News | Oncology Diagnostics | August 06, 2018
The Board of Directors of the Radiological Society of North America (RSNA) announced that Gary D. Luker, M.D., will...
Videos | Digital Radiography (DR) | August 03, 2018
Sheila Sferrella, president of Regents Health Resources and Bill Finerfrock, president of Capitol Associates, discuss
Videos | AAPM | August 03, 2018
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke Un...
New Regulatory Approvals Driving Research and Development Dollars in Medical Imaging Artificial Intelligence
News | Artificial Intelligence | August 01, 2018
Medical imaging has become the bellwether for the application of artificial intelligence (AI) technologies, especially...
Overlay Init